AD _____

GRANT NUMBER: DAMD17-94-J-4507

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors

PRINCIPAL INVESTIGATOR: Patricia A. Ganz, M.D.

CONTRACTING ORGANIZATION: University of California, Los Angeles Los Angeles, California 90024

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5102

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of Army position, policy or decision unless so designated by other documentation.

19980415 156

DTIC QUALITY INSPECTED 3

Davis Highway, Suite 1204. Arlington VA	and completing and reviewing the collection of ns for reducing this burden, to Washington He 22202-4302, and to the Office of Management	information. Send comments regard adquarters Services, Directorate for nt and Burget, Dans Services, Directorate for	iewing instructions, searching existing data sources, ding this burden estimate or any other aspect of this Information Operations and Reports, 1215 Jefferson Project (0704-0188), Washington, DC 20503.
1. AGENCY USE ONLY (Leave bl	nki 2. REPORT DATE	3. REPORT TYPE AN	
-	October 1997		ep 96 - 22 Sep 97)
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS
Managing Menopausal	Symptoms in Breast Car	ncer Survivors	
			DAMD17-94-J-4507
6. AUTHOR(S)			4
· · · · · · · · · · · · · · · · · · ·			
Patricia A. Ganz, M.	D.		
7. PERFORMING ORGANIZATION	NAME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER
		_	TEI OTT HOMBER
Los Angeles, Cal	lifornia, Los Ang	eles	
nos migeres, Cal			
9 SPONSOPINO/MONITOPINO			
9. SPONSORING/MONITORING A Commander	GENUT NAME(S) AND ADDRESS()	E9)	10. SPONSORING/MONITORING AGENCY REPORT NUMBER
U.S. Army Medical Rea	search and Materiel Co	ommand	
Fort Detrick, Freder	ick, Maryland 21702-S	5012	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABIL	ITY STATEMENT		12b. DISTRIBUTION CODE
	ITY STATEMENT release; distribution	unlimited	12b. DISTRIBUTION CODE
		unlimited	12b. DISTRIBUTION CODE
		unlimited	12b. DISTRIBUTION CODE
		unlimited	12b. DISTRIBUTION CODE
Approved for public 1	release; distribution		
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est	release; distribution	nly occur in breast ca	ancer survivors as a
Approved for public of 13. ABSTRACT (Maximum 200 Symptoms of essons of the second	release; distribution trogen deprivation commo ause, or menopause that is	nly occur in breast ca	incer survivors as a rely by
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est	trogen deprivation commo suse, or menopause that is strogen therapy with tamox	nly occur in breast ca precipitated prematu kifen. In this research	uncer survivors as a rely by
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of ess result of natural menopa chemotherapy or anti-ess evaluating the role of a program for managemen	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom	nly occur in breast ca precipitated prematu kifen. In this research a assessment (CMA) is in breast cancer sur	ancer survivors as a rely by a program, we are and intervention vivors. During the
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est evaluating the role of a program for management past funding year, we have	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we	nly occur in breast ca precipitated prematu kifen. In this research al assessment (CMA) is in breast cancer sur omen and randomizir	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-ca	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we are groups. The experimer	nly occur in breast ca precipitated prematu kifen. In this research a assessment (CMA) is in breast cancer sur omen and randomizin intal group receives in	ancer survivors as a rely by a program, we are and intervention vivors. During the og them into the amediate
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cast assessment and intervent	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, w	only occur in breast ca precipitated prematu kifen. In this research al assessment (CMA) is in breast cancer sur omen and randomizin ntal group receives in while the usual-care gr	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the amediate roup receives no
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cas assessment and intervent menopause related intervent	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont	nly occur in breast ca precipitated prematu kifen. In this research assessment (CMA) is in breast cancer sur omen and randomizin thal group receives in thile the usual-care gr th period of observati	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the amediate roup receives no ion. Systematic
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cat assessment and intervent menopause related intervent assessment of each bread	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom ave continued recruiting we are groups. The experiment tion for their symptoms, we vention during a four mont st cancer survivor assigned	nly occur in breast ca precipitated prematu kifen. In this research a assessment (CMA) is in breast cancer sur omen and randomizin that group receives in thile the usual-care gr th period of observati to the intervention g	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the amediate roup receives no ion. Systematic group permits
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopa chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cas assessment and intervent menopause related inter assessment of each breat treatment of multiple symptotic and treatment of multiple symptotic and treatment of multiple symptotic and the symptotic an	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously wi	only occur in breast ca precipitated prematu kifen. In this research al assessment (CMA) is in breast cancer sur omen and randomizin thal group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the amediate roup receives no ion. Systematic group permits atrogen
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of ess result of natural menopa chemotherapy or anti-ess evaluating the role of a program for managemen past funding year, we have experimental or usual-cas assessment and interven menopause related inter assessment of each breat treatment of multiple sympharmacologic, education	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously wi- onal and behavioral interver	nly occur in breast ca precipitated prematu kifen. In this research assessment (CMA) is in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the mediate roup receives no ion. Systematic group permits strogen ssessing the impact
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of ess result of natural menopa chemotherapy or anti-ess evaluating the role of a program for managemen past funding year, we have experimental or usual-cas assessment and interven menopause related inter assessment of each breat treatment of multiple sympharmacologic, education	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom ave continued recruiting we are groups. The experiment tion for their symptoms, we vention during a four mont st cancer survivor assigned	nly occur in breast ca precipitated prematu kifen. In this research assessment (CMA) is in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the mediate roup receives no ion. Systematic group permits strogen ssessing the impact
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of ess result of natural menopa chemotherapy or anti-ess evaluating the role of a program for managemen past funding year, we have experimental or usual-cas assessment and interven menopause related inter assessment of each breat treatment of multiple sympharmacologic, education of the intervention on que	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously wi- onal and behavioral interver	nly occur in breast ca precipitated prematu kifen. In this research assessment (CMA) is in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the amediate roup receives no ion. Systematic group permits strogen ssessing the impact pausal symptoms.
Approved for public a 13. ABSTRACT (Maximum 200 Symptoms of ess result of natural menopa chemotherapy or anti-ess evaluating the role of a program for managemen past funding year, we have experimental or usual-cas assessment and interven menopause related inter assessment of each breat treatment of multiple sympharmacologic, education of the intervention on que	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously wi- onal and behavioral interver	nly occur in breast ca precipitated prematu kifen. In this research assessment (CMA) is in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the mediate roup receives no ion. Systematic group permits strogen ssessing the impact
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopal chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cas assessment and intervent menopause related inter assessment of each breat treatment of multiple sympharmacologic, education of the intervention on quartal 14. SUBJECT TERMS	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa ant of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously wi- onal and behavioral interver	nly occur in breast ca precipitated prematu kifen. In this research assessment (CMA) is in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the amediate roup receives no ion. Systematic group permits strogen ssessing the impact pausal symptoms.
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopal chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cast assessment and intervent menopause related inter assessment of each breattreatment of multiple sympharmacologic, education of the intervention on quarter 14. SUBJECT TERMS Breast Cancer	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously with onal and behavioral interven- uality of life and the resolut	nly occur in breast ca precipitated prematu kifen. In this research al assessment (CMA) is in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as tion of specific menop	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the mediate roup receives no ion. Systematic group permits strogen ssessing the impact pausal symptoms. 15. NUMBER @F PAGES 8 16. PRICE CODE
Approved for public in 13. ABSTRACT (Maximum 200 Symptoms of est result of natural menopal chemotherapy or anti-est evaluating the role of a program for management past funding year, we have experimental or usual-cas assessment and intervent menopause related inter assessment of each breat treatment of multiple sympharmacologic, education of the intervention on quarters Breast Cancer	trogen deprivation commo ause, or menopause that is strogen therapy with tamox comprehensive menopausa at of menopausal symptom ave continued recruiting we are groups. The experimen- tion for their symptoms, we vention during a four mont st cancer survivor assigned mptoms simultaneously with onal and behavioral interven- uality of life and the resolut	only occur in breast ca precipitated prematu kifen. In this research al assessment (CMA) as in breast cancer sur omen and randomizin that group receives in while the usual-care gr th period of observati to the intervention g th a variety of non-es ntions. We will be as tion of specific meno	ancer survivors as a rely by a program, we are and intervention vivors. During the ag them into the mediate roup receives no ion. Systematic group permits strogen ssessing the impact pausal symptoms. 15. NUMBER OF PAGES 8 16. PRICE CODE

;

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

 \checkmark Where copyrighted material is quoted, permission has been obtained to use such material.

 \checkmark Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

MA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

MA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Patricia Harry Signature

Fund # DAMD17-94-J-4507

TABLE OF CONTENTS

Page Number

Front Cover	1
SF 298 Form	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5-7
Conculsion	7
Appendix	8
References	N/A

DOD Continuation Report

Introduction

Breast cancer is the leading cause of cancer in women, affecting 1 in 9 women in the U.S. According to the most recent SEER data, women with breast cancer have a relative 5-year survival rate of over 75%. Earlier detection of breast cancer, as well as improvements in post-operative adjuvant therapies, have enhanced the long term survival for women with this diagnosis. Symptoms of estrogen deprivation commonly occur in breast cancer survivors as a result of natural menopause, or menopause that is precipitated prematurely by chemotherapy or anti-estrogen therapy with tamoxifen. Hormone replacement therapy, the most efficacious treatment for these symptoms, is generally contraindicated in breast cancer. Thus, many breast cancer survivors endure considerable morbidity and impaired quality of life (QL) as a result.

This research program will evaluate the role of a comprehensive menopausal assessment (CMA) and intervention program for management of menopausal symptoms in breast cancer survivors. Using a randomized controlled design, we will assign symptomatic postmenopausal breast cancer survivors to an experimental or usual-care group. The experimental group will receive immediate assessment and intervention for their symptoms while the control group will receive no menopause related intervention during a four month period of observation. Systematic assessment of each breast cancer survivor assigned to the intervention will permit treatment of multiple symptoms simultaneously with a variety of non-hormonal pharmacologic, educational and behavioral interventions. The intervention program will be portable, and suitable for implementation in a variety of health care settings. We will evaluate the impact of the intervention on QL and the resolution of specific menopausal symptoms. OL will be assessed using standardized measures of health status, mood, and sexual functioning. Menopausal symptoms will be monitored using self-report diary cards. Our primary hypothesis is that the intervention program will lead to significant improvement in QL for breast cancer survivors.

Progress report on third year of funding

Recruitment and Subject Characteristics

During the past year, we continued accruing subjects for the randomized trial. As of October 1, 1997, a total of 177 women have been screened over the telephone. Of those, 108 (61%) were eligible and interested in participating in the study.

Women were found ineligible for four main reasons: Inadequate target symptoms (41%), Medical ineligibility (25%), Refusal to try our study medications (28%) and Already tried all our study medications (6%). There are no significant differences between the 69 ineligible women and the 108 eligible women in age, ethnicity, marital status, or tamoxifen use. Below are some demographic statistics from the two groups.

5

DOD Continuation Report

ູ້

	Eligible (N=108)	Not Eligible (N=69)
Mean Age	53.5	54.7
% White	88.9%	88.4%
% Married	65.8%	68.1%
% Currently Taking Tamoxifen	45.4%	51.5%

The current status of these 108 eligible women is as follows:

41 have completed the study

18 in the experimental group
23 in the usual care group

27 are currently in the study
2 are on hold
15 have dropped out voluntarily

8 had no time or were too busy
7 had other reasons

24 were determined to be ineligible for the study after an in-person evaluation

9 had inadequate target symptoms
9 had psychiatric difficulties
3 cancelled their appointments and refused to reschedule
2 refused to take study medications

1 had a problem filling in our forms

The attached Tracking Flow Chart (on page 8) gives more detail about how many women have completed each phase of the study. Subject recruitment has improved greatly over the past year, although we are still looking for ways to increase accrual (see below).

Because recruitment was lower and ineligibility was higher than anticipated, we have developed additional strategies for subject recruitment. We have regularly advertised in the Los Angeles Times, and have had other public service announcements of the study. We have also distributed announcements about the study at health fairs and through breast cancer support groups. We will continue to pursue all of these approaches to ensure completion of target accrual for the study.

Target Symptoms in Study Subjects


The three target symptoms under evaluation in this study are hot flashes, vaginal dryness and urinary incontinence. Among the 108 women eligible at the telephone screener, 92% reported severe hot flashes, 37% reported vaginal dryness and 14% reported stress incontinence. Thirty seven percent of entering women reported two or more of these symptoms. During the study, women report the frequency and severity of their target symptoms on baseline and follow-up questionnaires and also on diary cards, which they fill out on a daily basis for the four weeks preceding their baseline and their follow-up visits. Change in symptoms over time will be described in the two study groups.

Vaginal Scales Progress

A major portion of our work this year has involved the creation of two vaginal scales from the items on our Vaginal Exam Form. This form consists of 19 items filled out by the nurse practitioner at each woman's screening visit. We made a priori hypotheses about which items might be considered for the atrophy and inflammation scales, and then looked at correlations among those items and other related items from different forms to see if the scales would be plausible. We are currently working on two papers from these analyses. The first paper will describe the method of creating the two scales, and compare characteristics of women with different scores on these new scales. The second paper will describe the differences between women taking tamoxifen and women not taking tamoxifen on a variety of domains, including the two new vaginal scales.

Conclusion

During the past year the accrual rate has increased substantially but is still below what had been anticipated. Major barriers to participation include symptoms that are not severe enough for women to consider medication and the aversion to taking medication that women describe. Many women will take vitamins and herbal preparations, but are unwilling to take an FDA approved medication for symptom relief. Our recruitment efforts through advertising have been encouraging, and we will continue our efforts to publicize the study and recruit eligible subjects. Although the original research plan called for completion of recruitment in the third year of the study, we must extend recruitment into the fourth year of the research.



ب